Latest News

Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652

09/01/2023

The successful delivery of another Phase I clinical trial by the team at Simbec-Orion has resulted in the achievement of a significant milestone for Mission Therapeutics. MTX652 was shown to be well tolerated and safe up to a single dose of 200mg and multiple doses of 100mg once daily for 14 days. We share the […]

Read More

Sustained clinical response in a patient with metastatic breast cancer treated with MP0274

17/11/2022

Today we celebrate the success of our colleague, and Scientific Advisory Board member, Dr Samson Fung. Dr Fung was recently co-authored in a publication by JCO Precision Oncology released on 4th November, 2022, for his work as a study director in a Ph I FIH clinical study in patients with metastatic breast cancer. Believed to […]

Read More

Simbec-Orion supports AL-S Pharma with Phase II ALS Study

21/10/2022

Amyotrophic lateral sclerosis (ALS) is a rare, progressive neurodegenerative disease that affects the motor neurons controlling voluntary muscle movement. The onset is usually quite gradual, with patients noticing muscle weakness – including tripping or dropping things, in the early stages. Not all patients with ALS experience the same symptoms, and progression rate and survival time […]

Read More

Simbec-Orion Scientists Shortlisted for Wales STEM 2022 Finals

30/09/2022

We are proud to share that two of our Simbec-Orion colleagues are amongst the Welsh businesses and individuals shortlisted in the Wales STEM Awards 2022, which celebrate those making a difference to, and championing, Science, Technology, Engineering, and Maths (STEM) in Wales. The awards celebrate those leading the sector in Wales, those businesses creating an […]

Read More

Wales STEM Award Nominations for Two Simbec-Orion Scientists

30/09/2022

We are thrilled that two of our Simbec-Orion colleagues are amongst the Welsh businesses and individuals shortlisted in the Wales STEM Awards 2022, which celebrate those making a difference to, and championing, Science, Technology, Engineering, and Maths (STEM) in Wales. The awards celebrate those leading the sector in Wales, those businesses creating an impact on […]

Read More

Oxford Cannabinoid appoints Simbec-Orion to run first clinical trial on lead compound

28/09/2022

Simbec-Orion is honoured to have been trusted by Oxford Cannabinoid Technologies to conduct this milestone first-in-human, Phase1 clinical trial of its lead compound, OCT461201 for Postherpetic Neuralgia (PHN) & Irritable Bowel Syndrome. Chief Scientific Officer, Valentino Parravicini recently shared the excitement within OCT in reaching the clinical milestone and the significance of partnering with Simbec-Orion for […]

Read More

Simbec-Orion Adds to Client Support with Clinical Pharmacology Scientific Advisory Board

26/07/2022

Simbec-Orion is delighted to share the further expansion of our Clinical Pharmacology Scientific Advisory Board (SAB), with the recent appointment of Dr Kirsty Widenbach. Compared with traditional first-into-human studies, complex early phase studies with umbrella protocols or adaptive designs can offer critical data earlier whilst reducing cost. Such trials require a CRO that is both […]

Read More

Got a question?
Get in Touch or Submit an RFI/RFP

Our team is on hand to answer any questions you might have relating to the work we do at Simbec-Orion. Just fill in the form below, making sure to tick the boxes that apply, and we’ll respond as quickly as we can.

Looking to volunteer for a clinical trial?

Visit our dedicated volunteer website here, or email [email protected]

Follow us on Social Media

Name(Required)
Opt In Emails